Navigation Links
Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo

Demonstrates Positive Effect on Objective and Subjective Sleep Measures

MINNEAPOLIS, June 13, 2007 /PRNewswire-FirstCall/ -- According to study results presented today at SLEEP 2007, the 21st annual meeting of the Associated Professional Sleep Societies (APSS), VEC-162, a balanced melatonin (MT1/MT2) receptor agonist being developed by Vanda Pharmaceuticals Inc. , demonstrated improvements in objective and subjective measures of sleep onset and maintenance in a Phase III trial of transient insomnia.

VEC-162 was assessed in a randomized, double-blind, placebo-controlled, multi-center clinical trial that enrolled 412 adults in a sleep laboratory setting using a phase-advance, first-night assessment model of transient insomnia. The trial examined VEC-162 dosed 30 minutes before bedtime at 20, 50 and 100 mg versus placebo.

"Study patients reported they were falling asleep faster and staying asleep longer," said Tom Roth, Ph.D., Director of the Henry Ford Sleep Disorders and Research Center in Detroit, MI, presenter at today's APSS session. "These subjective measures support data collected in the sleep lab and provide an important dimension for assessing the efficacy of VEC-162."

VEC-162 demonstrated statistically significant improvements at all three tested doses compared to placebo (p<0.001) in the primary endpoint of the trial, Latency to Persistent Sleep (LPS), a measure of sleep onset. VEC-162 also produced statistically significant improvements relative to placebo in Latency to Non-Awake (LNA), another measure of sleep onset, Wake After Sleep Onset (WASO), a measure of sleep maintenance, and Total Sleep Time (TST). VEC-162 was also demonstrated to be safe and well tolerated.

VEC-162 also demonstrated improvements relative to placebo on subjective sleep measures. For LPS, all VEC-162 doses showed a trend toward improvement and 50 mg (p<0.001) and 100 mg (p=0.018) achieved statistical
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:8/28/2014)... -- Reportlinker.com announces that a new market research ... North America Aesthetic Lasers and Energy Devices Market ... North America Aesthetic Lasers and ... GlobalData,s new report, "North America Aesthetic Lasers ... key market data on the North America Aesthetic ...
(Date:8/28/2014)... , Aug. 28, 2014 ... research report is available in its ... and Compliance Services Industry (U.S.): Analytics, ... Forecasts to 2021, NAIC 541380 ... Testing Laboratories, Safety and ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: Germany Aesthetic Lasers and Energy ... http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Germany Aesthetic Lasers ... Summary GlobalData,s new report, "Germany Aesthetic Lasers ... key market data on the Germany Aesthetic Lasers ...
Breaking Medicine Technology:North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9
... ATLANTA, Georgia, May 30 The International,Diabetes ... fund a lifestyle intervention trial that seeks ... type 2 diabetes in Chennai, India., ... community based diabetes prevention programme will determine,optimal ...
... children under 3 years old with diffuse,pontine glioma compared ... cancer may be distinct in young patients, MEMPHIS, ... have shown that children under 3 years old,who have ... to have a,better outcome than older children with the ...
Cached Medicine Technology:International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India 2International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India 3St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors 2St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors 3
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Dr. Parsa ... late stages of hair loss achieve great results in hair ... Facial Hair Transplant , an FUE method that harvests ... area. This method lets patients whose hair loss classification ... Facial Hair Transplant is a great alternative for those advanced ...
(Date:8/29/2014)... La Miraca, California (PRWEB) August 29, 2014 ... clinical training to Chapman University Physical Therapy students ... students at Chapman University will be shadowing Healthpointe ... which will allow them to develop clinical experience ... University Physical Therapy students will gain insight into ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Astronauts ... travel appears to disrupt human immune systems, a new ... on any long missions to asteroids, the moon and ... or flu while in space can be dangerous, NASA ... immune cells in the blood of International Space Station ...
(Date:8/29/2014)... Pursuing its deepest desires to help build ... stunning new design that promises to redefine the global ... surrogacy platform has witnessed a 42 percent increase in ... month, the FindSurrogateMother.com community is formed by hopeful parents ... — the precious gift of life. , Whether intended ...
(Date:8/29/2014)... Healthpointe Medical Group, one of ... center from LAXMed. The medical center is less than 2 ... west of the 405 freeway. , The LAX clinic ... LAX center is located at: 8610 S. Sepulveda Blvd., Suite ... Healthpointe LAX office will provide the same comprehensive services ...
Breaking Medicine News(10 mins):Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... Starpharma saw an 8% increase in its share, following approval ... prevent transmission of HIV. // The company even signed ... of Allergy and Infectious Diseases, an integral part of the ... approved products for the prevention of HIV infection. The FDA ...
... balance its usage between office work and private life, as ... instructions and work during evenings and weekends //when they are ... and during office hours they find the mobile phones and ... of office time and work concentration. Most of the people ...
... soldiers for experiments for finding a vaccine for Hepatitis. ... while serving abroad. Hepatitis E is reported to account ... //In 1995, the US Armed Forces Research Institute of ... Army Institute of Research, set up a unit in ...
... the primary diseases affecting the children below two years. It ... the end of November and the incidence increases and reaches ... Lehman, MD, associate director of pediatric infectious diseases and HIV ... about the disease and this situation has to change. ...
... Population Fund, in 2005 than in any year since its ... 171.// ,In 2004, 166 nations had contributed to UNFPA. ... 2005. Contributions to the UNFPA regular resources last year were ... previous year's level of $322 million. The top six donors ...
... said China has improved its capability to handle epidemic ... SARS epidemic in 2003 exposed the flaws in China's ... comprehensive steps to address them, he said. ,After ... end of 2005, the goal of an improved and ...
Cached Medicine News:Health News:Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission 2Health News:US Reportedly Experimenting on Nepali Soldiers 2Health News:Parental Knowledge Of RSV Infections Is Vital 2Health News:Record Number of Countries Contributed to UNFPA in 2005 2
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
Medicine Products: